NG-641 for Advanced Cancer
(STAR Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new treatment called NG-641 to see if it is safe for patients with advanced or spreading epithelial tumors. The treatment is given through an IV, and researchers are trying to find the best dose.
Who Is on the Research Team?
Haesong Park, MD
Principal Investigator
Washington University School of Medicine, St Louis, Missouri
Are You a Good Fit for This Trial?
This trial is for adults with advanced epithelial cancers that have failed standard treatments or have no standard options left. Participants must be expected to live at least 6 months, have tumors that can be biopsied safely, and function well in daily life (ECOG status 0-1). They should not have had certain vaccines, major surgeries, or specific treatments recently and must not have active infections or severe autoimmune diseases.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1a Treatment
Dose-escalation and dose-optimization phase with NG-641 administration by IV infusion
Phase 1b Treatment
Investigation of optimized multicycle dosing regimen as monotherapy in specific tumour types
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- NG-641
Find a Clinic Near You
Who Is Running the Clinical Trial?
PsiOxus Therapeutics Ltd
Lead Sponsor
Akamis Bio
Lead Sponsor